News
Homepage
/
News
/
In 2016
/
Congratulations to the successful conclusion of the 2016 CPhI Worldwide exhibition

News classification

Check category

News Center

Viwit Pharmaceutical’s Lifitegrast API has completed registrations in both China and the US! 2024-08-14 11:55:51
Recently, Viwit Pharmaceutical’s self-developed Lifitegrast API has completed the registrations in China and the United States. The API registration number is Y20240000726, and the US DMF number is 040172.
Viwit Pharmaceutical's Varenicline Tartrate Tablet receives official approval from South Africa 2024-07-15 10:01:41
Recently, theViwit independently developed smoking cessation drug Varenicline (Tartrate) Tablets, in strengths of 0.5 mg and 1 mg, received the Drug Registration Certificate issued by the South African Health Products Regulatory Authority (SAHPRA).
Viwit Pharmaceutical's Fosaprepitant Dimeglumine API Receives Official Approval from NMPA 2024-07-12 09:12:19
On July 5, 2024, Viwit Pharmaceitical’s independently developed Fosaprepitant Dimeglumine API received the "Notice of Approval of Application for Listing of Chemical APIs" issued by National Medical Products Administration (NMPA). The registration number is Y20220000736, and the notice number is 2024YS00664.
Viwit Pharmaceuticals' Bimatoprost Eye Drops Receive Official Approval by China NMPA 2024-07-09 10:54:01
Recently, Viwit Pharmaceuticals received the "Drug registration certificate" issued by China National Medical Products Administration (NMPA) for Bimatoprost Eye Drops. The approval number is H20244103. This signifies that the product has received official approval for the Chinese market and has successfully passed the generic drug consistency evaluation, thereby becoming the second domestic generic drug of its kind.
Viwit Pharmaceuticals' Gadoterate Meglumine Injection Receives Official Approval by China NMPA 2024-06-17 15:13:15
Viwit Pharmaceuticals proudly announces the receipt of the "Drug Supplementary Application Approval Notice" from the National Medical Products Administration (NMPA) for their Gadoterate Meglumine Injection. This approval includes the following strengths: 10 mL containing 3.769 g, 15 mL containing 5.654 g, and 20 mL containing 7.538 g. The corresponding approval numbers are H20243899, H20243900, and H20243901.
Viwit Pharmaceuticals' Deslanoside Injection Receives Official Approval by China NMPA 2024-06-15 10:26:00
May 8, 2024 – Viwit Pharmaceuticals proudly announces the receipt of the "Drug Supplementary Application Approval Notice" from the National Medical Products Administration (NMPA) for the drug product, Deslanoside Injection. The approval notice number is 2024B01980.

Congratulations to the successful conclusion of the 2016 CPhI Worldwide exhibition

  • Categories:In 2016
  • Author:
  • Origin:
  • Time of issue:2016-10-24 01:09

(Summary description)Congratulations on the successful conclusion of the 2016 World Pharmaceutical Raw Materials Europe Exhibition, and thank all the new and old customers who came to the site for their trust and support. Through this exhibition, we have deepened cooperation with customers and laid the foundation for further expanding the market. We will continue to work hard to create value for our customers.

website

website

Congratulations to the successful conclusion of the 2016 CPhI Worldwide exhibition

(Summary description)Congratulations on the successful conclusion of the 2016 World Pharmaceutical Raw Materials Europe Exhibition, and thank all the new and old customers who came to the site for their trust and support. Through this exhibition, we have deepened cooperation with customers and laid the foundation for further expanding the market. We will continue to work hard to create value for our customers.

  • Categories:In 2016
  • Author:
  • Origin:
  • Time of issue:2016-10-24 01:09
  • Views:
Information

Congratulations on the successful conclusion of the 2016 World Pharmaceutical Raw Materials Europe Exhibition, and thank all the new and old customers who came to the site for their trust and support. Through this exhibition, we have deepened cooperation with customers and laid the foundation for further expanding the market. We will continue to work hard to create value for our customers.

Scan the QR code to read on your phone

Previous: Congratulations to Viwit Pharmaceutical Co.,Ltd
Next: Congratulations to Viwit Pharmaceutical Co.,Ltd for passing Cofepris certification of the Ministry of Health of Mexico
Previous: Congratulations to Viwit Pharmaceutical Co.,Ltd
Next: Congratulations to Viwit Pharmaceutical Co.,Ltd for passing Cofepris certification of the Ministry of Health of Mexico
search
Confirm
Close
About Us
Company Introduction Corporate History Business Introduction Corporate Governance Company Culture Corporate Honors Viwit Family Media Center Video
R&D and Innovation
R&D Innovation Product Pipeline Achievements
Products
Drug Products Biologics APIs Intermediates Boranes OLED Materials
Innovation
CDMO Project Collaboration In-/Out-Licensing Joint Venture
Sustainable
EHS Energy Quality Supplier
News Center
In 2024 In 2023 In 2022 In 2021 In 2020
Join Us
Talent Philosophy Talent Development Salary and Benefits Campus Recruiting Social Recruitment
Contact Us
Online Message Contact Us
dp EN
dp 中文

wz

wz